keyword
MENU ▼
Read by QxMD icon Read
search

NATA

keyword
https://www.readbyqxmd.com/read/28231566/one-year-outcomes-of-1-pro-re-nata-versus-3-pro-re-nata-intravitreal-aflibercept-injection-for-neovascular-age-related-macular-degeneration
#1
Kei Takayama, Hiroki Kaneko, Tadasu Sugita, Ruka Maruko, Kyoko Hattori, Eimei Ra, Kenichi Kawano, Keiko Kataoka, Yasuki Ito, Hiroko Terasaki
PURPOSE: We compared 1-year outcomes of 1 + pro re nata (PRN) versus 3 + PRN of intravitreal aflibercept injection (IAI) for age-related macular degeneration (AMD). METHODS: Forty-two eyes with naïve AMD received 3 + PRN IAI treatment and 47 eyes with naïve AMD received 1 + PRN IAI treatment. Visual acuity (VA), central retinal thickness (CRT), and central choroidal thickness (CCT) and number of administered IAIs during 12 months were compared. RESULTS: VAs improved, and CRTs reduced significantly at any given month from baseline in both groups (p < 0...
February 24, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28192841/6-year-results-of-cnv-secondary-to-pathological-myopia-treated-with-ranibizumab
#2
L Hefner, H Gerding
Background The current standard treatment of choroidal neovascularisation (CNV) secondary to pathological myopia (PM) is intravitreal injection of VEGF antagonists. We now present our 6-year results after treating patients with CNV secondary to PM with ranibizumab. Patients and Methods We retrospectively analysed 15 treatment-naive eyes of 13 patients (10 women, 3 men, mean age 59.2; standard deviation (SD) 11.1; range 41-78 years) with visual impairment related to CNV secondary to PM, who were treated with at least 1 injection of ranibizumab...
February 13, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28188433/the-clinical-effectiveness-of-ranibizumab-treat-and-extend-regimen-in-namd-systematic-review-and-network-meta-analysis
#3
REVIEW
Andriy Danyliv, Julie Glanville, Rachael McCool, Alberto Ferreira, Adrian Skelly, Ruth Pulikottil Jacob
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is a chronic eye condition that causes severe deterioration of vision and ultimately blindness. Two vascular endothelial growth factor inhibitors are approved for nAMD treatment in Europe: ranibizumab and aflibercept. The European license for ranibizumab was updated with an individualized "treat and extend" (T&E) regimen, which involves more proactive treatment based on changes in best corrected visual acuity (BCVA) and/or anatomical outcomes...
February 10, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28183240/pharmacotherapy-of-persons-with-dementia-in-long-term-care-in-australia-a-descriptive-audit-of-central-nervous-system-medications
#4
Wendy Moyle, Najwan El Saifi, Brian Draper, Cindy Jones, Elizabeth Beattie, David Shum, Lukman Thalib, Cindy Mervin, Siobhan O Dwyer
BACKGROUND: Neuropsychiatric symptoms of dementia are often treated through the prescription of one or more psychotropic medications. However, limited efficacy and potential harmful side-effects has resulted in efforts to reduce the use of psychotropic medication in this population, particularly for those living in long-term care. OBJECTIVES: This study sought to describe the pattern of central nervous system medication usage in older adults with dementia living in long-term care; assess the appropriateness of prescribing against Beers criteria; and detect potential drug interactions from co-administered medications...
February 9, 2017: Current Drug Safety
https://www.readbyqxmd.com/read/28174600/does-accreditation-improve-pro-re-nata-benzodiazepines-administration-in-psychiatric-inpatients-pre-post-accreditation-medical-record-comparison
#5
Mohammed Abdullah Al-Sughayir
BACKGROUND: In psychiatric inpatients, administration of pro re nata benzodiazepines is a common practice. Benzodiazepine use is associated with potential complications of risk of abuse, cognitive impairment, and falls. An interest in accreditation is growing rapidly among many countries to enhance the quality of health care services. We aimed to investigate whether hospital accreditation drives improvements for administered pro re nata benzodiazepines in psychiatric inpatients. METHODS: The study reviewed medical records of consecutive hospital admissions for pre- and post-accreditation comparisons of PRN benzodiazepine medications in two acute mental health wards at a teaching general hospital...
2017: International Journal of Mental Health Systems
https://www.readbyqxmd.com/read/28151839/angiopoietin-like-4-correlates-with-response-to-intravitreal-ranibizumab-injections-in-neovascular-age-related-macular-degeneration
#6
Jong Ho Kim, Jae Pil Shin, In Taek Kim, Dong Ho Park
PURPOSE: To investigate whether the aqueous angiopoietin-like 4 (ANGPTL4) level correlates with clinical features in neovascular age-related macular degeneration (AMD). METHODS: The control and study groups consisted of all consecutive patients who received senile cataract surgery or intravitreal ranibizumab injection for treatment-naïve neovascular AMD, respectively. The AMD group received 3 monthly ranibizumab injections followed by monthly pro re nata for at least 12 months...
February 1, 2017: Retina
https://www.readbyqxmd.com/read/28144918/a-retrospective-study-of-ranibizumab-treatment-regimens-for-neovascular-age-related-macular-degeneration-namd-in-australia-and-the-united-kingdom
#7
Robert L Johnston, Hans-Joachim Carius, Adrian Skelly, Alberto Ferreira, Fran Milnes, Paul Mitchell
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss among persons aged 65 years and older. Anti-vascular endothelial growth factor (anti-VEGF) treatment is the recommended standard of care. The current study compares the effectiveness of ranibizumab in routine clinical practice in two countries that generally apply two different treatment regimens, treat-and-extend (T&E) in Australia or pro re nata (PRN) in the UK. METHODS: This retrospective, comparative, non-randomised cohort study is based on patients' data from electronic medical record (EMR) databases in Australia and the UK...
January 31, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28139100/dexamethasone-implant-with-fixed-or-individualized-regimen-in-the-treatment-of-diabetic-macular-oedema-six-month-outcomes-of-the-udbasa-study
#8
Valentina Sarao, Daniele Veritti, Claudio Furino, Ermete Giancipoli, Giovanni Alessio, Francesco Boscia, Paolo Lanzetta
PURPOSE: To evaluate a pro re nata administration of Ozurdex(®) implant versus a single administration for treating diabetic macular oedema (DME). METHODS: This exploratory study is designed as a comparative, multicentre, randomized study with a follow-up of 6 months. Patients with DME were assigned to treatment at baseline either with a single Ozurdex(®) implant during the entire six-month follow-up (fixed group) or Ozurdex(®) implant followed by retreatment on an individualized basis (PRN group)...
January 31, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28139082/switching-from-pro-re-nata-to-treat-and-extend-regimen-improves-visual-acuity-in-patients-with-neovascular-age-related-macular-degeneration
#9
Line Kvannli, Jørgen Krohn
PURPOSE: To evaluate the visual outcome after transitioning from a pro re nata (PRN) intravitreal injection regimen to a treat-and-extend (TAE) regimen for patients with neovascular age-related macular degeneration (AMD). METHODS: A retrospective review of patients who were switched from a PRN regimen with intravitreal injections of bevacizumab, ranibizumab or aflibercept to a TAE regimen. The best corrected visual acuity (BCVA), central retinal thickness (CRT) and type of medication used at baseline, at the time of changing treatment regimen and at the end of the study were analysed...
January 31, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28119292/intravitreal-ziv-aflibercept-for-the-treatment-of-choroidal-neovascularisation-associated-with-conditions-other-than-age-related-macular-degeneration
#10
Imoro Zeba Braimah, Michael Stewart, Chetan Videkar, Chintan J Dedhia, Jay Chhablani
AIM: To report the short-term outcomes of eyes with choroidal neovascularisation (CNV) associated with causes other than age-related macular degeneration (AMD) after treatment with intravitreal ziv-aflibercept (IVZ) injections. METHODS: This retrospective study included eyes with non-AMD-related CNV that were treated with IVZ (1.25 mg/0.05 mL) on a pro re nata basis. The primary outcome measure is the mean change in best-corrected visual acuity (BCVA) and secondary outcome measures include the mean change in central macular thickness (CMT) and adverse events...
January 24, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28114697/-strategies-of-intravitreal-injections-with-anti-vegf-pro-re-nata-versus-treat-and-extend
#11
K Hufendiek, A Pielen, C Framme
The goal of this report is to provide a review on different strategies for the use of pro re nata (PRN) and treat and extend (T&E) regimens with intravitreal anti-VEGF agents (bevacizumab, ranibizumab or aflibercept) in patients with retinal diseases such as neovascular AMD, diabetic macular oedema and macular oedema due to retinal vein occlusion. The main focus is to present the effectiveness and visual outcomes of both PRN and T&E regimens in the main pivotal trials and studies based on currently available evidence...
January 23, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28102456/efficacy-and-safety-of-a-fixed-bimonthly-ranibizumab-treatment-regimen-in-eyes-with-neovascular-age-related-macular-degeneration-results-from-the-rabimo-trial
#12
Nicolas Feltgen, Thomas Bertelmann, Mirko Bretag, Sebastian Pfeiffer, Reinhard Hilgers, Josep Callizo, Lena Goldammer, Sebastian Bemme, Hans Hoerauf
PURPOSE: To evaluate prospectively the efficacy and safety of a fixed bimonthly ranibizumab treatment regimen (RABIMO) in eyes with neovascular age-related macular degeneration (nAMD) and to compare these results with a pro re nata (PRN) treatment scheme. METHODS: This was a 12-month, phase IV, single center, randomised, non-inferiority study. Following three initial monthly injections, patients were randomised to receive either ranibizumab bimonthly (RABIMO group) or ranibizumab PRN (PRN group) (n = 20 each)...
January 19, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28077156/interventions-following-a-high-violence-risk-assessment-score-a-naturalistic-study-on-a-finnish-psychiatric-admission-ward
#13
Jenni Kaunomäki, Markus Jokela, Raija Kontio, Tero Laiho, Eila Sailas, Nina Lindberg
BACKGROUND: Patient aggression and violence against staff members and other patients are common concerns in psychiatric units. Many structured clinical risk assessment tools have recently been developed. Despite their superiority to unaided clinical judgments, staff has shown ambivalent views towards them. A constant worry of staff is that the results of risk assessments would not be used. The aims of the present study were to investigate what were the interventions applied by the staff of a psychiatric admission ward after a high risk patient had been identified, how frequently these interventions were used and how effective they were...
January 11, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28049547/palliative-care-during-the-final-week-of-life-of-older-people-in-nursing-homes-a-register-based-study
#14
Jonas Smedbäck, Joakim Öhlén, Kristofer Årestedt, Anette Alvariza, Carl-Johan Fürst, Cecilia Håkanson
OBJECTIVE: Our aim was to explore the presence of symptoms, symptom relief, and other key aspects of palliative care during the final week of life among older people residing in nursing homes. METHOD: Our study employed data from the Swedish Palliative Care Register on all registered individuals aged 60 and older who had died in nursing homes during the years 2011 and 2012. Variables pertaining to monitoring and treatment of symptoms, end-of-life discussions, circumstances around the death, and the individual characteristics of deceased individuals were explored using descriptive statistics...
January 4, 2017: Palliative & Supportive Care
https://www.readbyqxmd.com/read/28048946/intravitreal-anti-vascular-endothelial-growth-factor-drugs-for-retinal-angiomatous-proliferation-in-real-life-practice
#15
Maurizio Battaglia Parodi, Simone Donati, Francesco Semeraro, Paola Danzi, Ugo Introini, Francesco Viola, Ferdinando Bottoni, Vincenzo Pucci, Andrea Musig, Alfredo Pece, Claudio Azzolini
PURPOSE: To describe the outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in the treatment of retinal angiomatous proliferation (RAP) in real-life practice in 7 Italian centers under the Progetto Luce initiative. METHODS: Clinical data of 95 eyes of 95 patients affected by RAP, regularly followed up and treated with either intravitreal ranibizumab or bevacizumab over 12 months, were examined. After a loading phase of 3 consecutive injections, retreatments were administered following a pro-re-nata regimen on the basis of the persistence or the recurrence of subretinal/intraretinal fluid on optical coherence tomography, or leakage on fluorescein angiography...
March 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28033280/stereotactic-radiotherapy-in-neovascular-age-related-macular-degeneration-real-life-efficacy-and-morphological-evaluation-of-the-outer-retina-choroid-complex
#16
Mahdy Ranjbar, Maximilian Kurz, Annekatrin Holzhey, Corinna Melchert, Dirk Rades, Salvatore Grisanti
Stereotactic radiotherapy (SRT) is a new approach to treat neovascular age-related macular degeneration (nAMD). The INTREPID trial suggested that SRT could reduce the frequency of regular intravitreal injections (IVIs) with antivascular endothelial growth factor drugs, which are necessary to control disease activity. However, the efficacy of SRT in nAMD and resulting morphological changes have not been validated under real-life circumstances, an issue, which we would like to address in this retrospective analysis...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28033235/factors-influencing-visual-acuity-in-patients-receiving-anti-vascular-endothelial-growth-factor-for-myopic-choroidal-neovascularization
#17
Pierluigi Iacono, Maurizio Battaglia Parodi, Federico Selvi, Maria Cristina Parravano, Adele Chiaravalloti, Monica Varano, Francesco Bandello
PURPOSE: To identify the prognostic variables relative to myopic choroidal neovascularization (CNV) treated with intravitreal ranibizumab/bevacizumab. METHODS: Forty-eight patients with myopic CNV were enrolled in a prospective, interventional, non-randomized 12-month study. Intravitreal ranibizumab/bevacizumab was administered in a pro-re-nata regimen and re-treatment was performed in the presence of angiographic leakage, intraretinal/subretinal fluid on optical coherence tomography, new hemorrhages, five-letter decrease and increased metamorphosia...
December 28, 2016: Retina
https://www.readbyqxmd.com/read/28031699/long-term-follow-up-of-patients-with-choroidal-neovascularization-due-to-angioid-streaks
#18
Maria Guadalupe Martinez-Serrano, Abelardo Rodriguez-Reyes, Jose Luis Guerrero-Naranjo, Guillermo Salcedo-Villanueva, Jans Fromow-Guerra, Gerardo García-Aguirre, Virgilio Morales-Canton, Raul Velez-Montoya
BACKGROUND: The following case series describes the long-term anatomical and functional outcome of a group of seven patients with choroidal neovascularization (CNV), secondary to angioid streaks (AS), who were treated with antiangiogenic drugs in a pro re nata (PRN) regimen. After the 4-year mark, visual acuity tends to return to pretreatment level. Treatment delays and lack of awareness and self-referral by the patients are believed to be the cause of the PRN regimen failure. PURPOSE: To assess the long-term outcomes (>4 years) of patients with CNV due to AS treated with a PRN regimen of antiangiogenic...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28008223/physician-patient-and-caregiver-experience-of-different-wet-age-related-macular-degeneration-anti-vegf-treatment-regimens-in-japan-a-qualitative-assessment
#19
Tomohiro Iida, Keirei Ishii
PURPOSE: The purpose of this study was to monitor anti-vascular endothelial growth factor (anti-VEGF) treatment regimens for wet age-related macular degeneration (wAMD) in clinical practice and to determine how they impact the physician, patient, and caregiver treatment experience. MATERIALS AND METHODS: This was a qualitative analysis based on semistructured interviews with 20 ophthalmologists who had practiced both pro re nata (PRN) and treat-and-extend (T&E) anti-VEGF regimens for wAMD...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28007451/quantitative-changes-in-pigment-epithelial-detachment-area-and-volume-predict-retreatment-in-polypoidal-choroidal-vasculopathy
#20
Errol W Chan, Mohab Eldeeb, Gopal Lingam, Doneal Thomas, Mayuri Bhargava, Caroline K Chee
PURPOSE: To determine if changes in pigment epithelial detachment (PED) area and volume predict retreatment in polypoidal choroidal vasculopathy (PCV). DESIGN: Retrospective case-control study METHODS: PCV patients on pro-re-nata (PRN) anti-vascular endothelial growth factor (VEGF) therapy with >1 year follow-up at an academic retina service were included. Monthly anti-VEGF injections were given until a dry macula was achieved, and treatment deferred. Retreatment indication was recurrence of intraretinal or subretinal fluid, or new hemorrhage...
December 19, 2016: American Journal of Ophthalmology
keyword
keyword
81148
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"